Trial Profile
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Cardiovascular disorders; Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms REDUCE-IT; REDUCE-IT CABG; REDUCE-IT DIABETES
- Sponsors Amarin Corporation; Amarin Pharmaceuticals
- 08 Apr 2024 According to an HLS Therapeutics media release, REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were published online today in the 73rd Annual Scientific Sessions of the American College of Cardiology (ACC.24)
- 08 Apr 2024 Results published in the Media Release
- 06 Apr 2024 Results presented in an Amarin Corporation media release.